BioCryst Acquires Astria for $700 Million to Enhance HAE Treatment Options

BioCryst Pharmaceuticals has announced its acquisition of Astria Therapeutics for approximately $700 million. This strategic move aims to enhance BioCryst’s portfolio in the rare disease market, specifically targeting hereditary angioedema (HAE), a condition characterized by debilitating swelling attacks.

With the acquisition, BioCryst aims to introduce a new injectable drug, navenibart, which could allow patients to reduce their frequency of injections to as few as two per year. This contrasts with current injectable treatments that require administration every two weeks to once a month. BioCryst, based in Durham, North Carolina, currently markets Orladeyo, a daily oral medication aimed at preventing HAE attacks, representing a significant addition to its offerings in this competitive space.

Strategic Implications of the Acquisition

BioCryst’s acquisition of Astria is particularly significant as the market for HAE therapies is becoming increasingly crowded. The company has positioned itself as a key player in this field with Orladeyo, which generated $437.6 million in sales last year. An FDA decision regarding an oral granule formulation of Orladeyo for children aged 2 to 11 is anticipated by December 12, 2023.

The competitive landscape includes notable rivals such as Takeda Pharmaceutical, which offers Takhzyro, a drug approved in 2018 requiring injections every two weeks. New entrants into the market include CSL Behring, with its recently approved Andembry, and Ionis Pharmaceuticals, which received approval for Dawnzera this past summer.

Astria’s product, navenibart, is currently in a global Phase 3 clinical trial. This trial is evaluating various dosing regimens, including 600 mg followed by 300 mg every three months and 600 mg every six months. The primary endpoint is the frequency of HAE attacks over a six-month treatment period, with preliminary results expected by early 2027.

Market Potential and Future Growth

BioCryst’s acquisition also reflects its long-term growth strategy. The company estimates that its HAE portfolio could generate up to $1 billion in revenue by 2029, potentially exceeding $1.8 billion by 2033. This projection underscores the importance of navenibart as a next-generation therapy that could significantly improve patient outcomes through reduced injection frequency and enhanced efficacy.

BioCryst’s Chief Commercial Officer, Charlie Gayer, emphasized the importance of addressing patient needs for less burdensome dosing schedules. He noted that while current therapies adequately meet efficacy requirements, the market is increasingly focused on minimizing the injection burden on patients. Navenibart’s potential to offer three- to six-month dosing intervals could make it a preferred choice among patients seeking more convenient treatment options.

The deal, which is valued at approximately $8.55 in cash and 0.58 shares of BioCryst common stock per Astria share, is based on BioCryst’s stock price as of October 8, 2023. This valuation represents a 53% premium compared to Astria’s closing price before the announcement. BioCryst has also secured up to $550 million in debt financing to support the transaction, with some of these funds earmarked for the cash portion of the acquisition.

Pending regulatory approvals and shareholder consent, the acquisition is expected to finalize in the first quarter of 2026. Upon completion, Astria’s CEO, Jill Milne, will join BioCryst’s board, and Astria shareholders will hold approximately 15% of the combined entity.

In addition to navenibart, Astria’s pipeline includes STAR-0310, an antibody targeting the inflammatory protein OX40 for potential atopic dermatitis treatment. However, BioCryst plans to explore strategic alternatives for this asset, as it does not align with their focus on rare diseases.

This acquisition positions BioCryst to not only maintain but potentially expand its influence in the rare disease market, particularly in the critical area of hereditary angioedema treatment.